GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Hester Biosciences Ltd

Hester Biosciences Q2 FY27 PAT Rises 131.06% to INR 166.60 Million; USD 1M Loan to Subsidiary

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 05 Nov 2026, 11:16 AM IST  ·  BSE ID: 6fa56bfd-9100-454c-9310-5587746e89b6
View Original BSE Filing (PDF)
💡
In Simple Terms
Hester Biosciences' quarterly profit more than doubled, and it approved a USD 1 million loan to its African subsidiary.
🤖 AI Summary
  • Hester Biosciences Q2 FY27 standalone Profit After Tax (PAT) increased 131.06% to INR 166.60 Million.
  • Q2 FY27 revenue from operations reached INR 829.28 Million.
  • The board approved an unsecured loan of USD 1 million to Hester Biosciences Africa Limited.
  • The loan to the wholly-owned subsidiary has a 9% annual interest rate and a three-year tenure.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from Operations (Q2 FY27)
829.28 Million
Profit After Tax (Q2 FY27)
166.60 Million
131.06%
Loan to Hester Africa
USD 1 million
Loan Interest Rate
9% per annum
Earnings Per Share (Q2 FY27)
19.59 INR
🏢 How This Affects the Company
📈
Business Impact
The loan to Hester Biosciences Africa Limited supports the subsidiary's business and working capital needs, potentially enhancing its operational scale and market presence in Africa. This internal financing aligns with strategic objectives for foreign wholly-owned subsidiaries.
💰
Financial Impact
Hester Biosciences' standalone Profit After Tax increased to INR 166.60 Million for Q2 FY27. The USD 1 million unsecured loan to its subsidiary will generate interest income at 9% per annum for the parent company over three years.
⚙️
Operational Impact
The USD 1 million loan provides Hester Biosciences Africa Limited with funds for business and general corporate purposes, including working capital, directly supporting its operational continuity and growth initiatives.
⚠️
Risk Impact
The unsecured nature of the USD 1 million loan to Hester Biosciences Africa Limited introduces a credit risk for the parent company, Hester Biosciences, India, in case of default by the subsidiary. However, as a wholly-owned subsidiary, the parent has full control.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this filing.
👤
Who Is Affected
All shareholders are indirectly affected by the company's financial performance, including the 131.06% increase in Q2 FY27 PAT to INR 166.60 Million and the strategic decision to provide a USD 1 million loan to a subsidiary.
🔍
Management Signal
Management is signaling a focus on both enhancing standalone profitability and supporting the growth and operational requirements of its international subsidiaries through internal financing.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — assess continued profitability growth and revenue from operations.
Hester Africa loan utilization — monitor if the loan supports stated business and working capital purposes.
Financial updates from Hester Africa — track its performance and ability to service the loan.
LOW RISK The unsecured loan to a wholly-owned subsidiary introduces minimal direct risk to the parent company.
💡 Investor Takeaway
Hester Biosciences reported standalone Profit After Tax of INR 166.60 Million for Q2 FY27, a 131.06% increase from INR 72.09 Million in Q2 FY26. The board approved a USD 1 million unsecured loan to its wholly-owned subsidiary, Hester Biosciences Africa Limited, at 9% interest for three years.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone Profit After Tax for Q2 FY27 significantly grew to INR 166.60 Million, demonstrating strong profitability.
  • Revenue from Operations for Q2 FY27 increased to INR 829.28 Million compared to INR 645.79 Million in Q2 FY26.

⚠️ Concerns

  • The USD 1 million loan to the wholly-owned subsidiary is unsecured, presenting a direct credit risk to Hester Biosciences as the lender.
  • Change in inventories of finished goods, traded goods and work in progress showed a negative of (INR 26.54) Million in Q2 FY27.
📅 Company Track Record
Hester Biosciences has demonstrated consistent growth in profitability, with Q1 FY27 standalone PAT jumping 87.69% to INR 147.11 Million and FY26 standalone PAT rising 64% to INR 521.00 Million. The company also proposed an INR 11 dividend in FY26.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Hester Biosciences' standalone net profit for Q2 FY27?
Hester Biosciences reported a standalone Profit After Tax of INR 166.60 Million for the quarter ended 30 September 2026 (Q2 FY27).
How much did Hester Biosciences' Q2 FY27 standalone PAT increase year-over-year?
The standalone Profit After Tax for Q2 FY27 increased by 131.06% to INR 166.60 Million compared to INR 72.09 Million in Q2 FY26.
What was Hester Biosciences' revenue from operations in Q2 FY27?
Revenue from Operations for Hester Biosciences in Q2 FY27 was INR 829.28 Million.
What loan did Hester Biosciences' board approve for its subsidiary?
The board approved an unsecured loan of USD 1 million to Hester Biosciences Africa Limited, its foreign wholly-owned subsidiary.
What are the key terms of the USD 1 million loan to Hester Biosciences Africa Limited?
The loan is unsecured, carries an interest rate of 9% per annum, and has a tenure of 3 (Three) years from the first drawdown date.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.